Levetiracetam Treatment of Tardive Dyskinesia

Yale University

Status and phase: Completed; Phase 3

Conditions: Tardive Dyskinesia

Treatments: Drug: placebo; Drug: levetiracetam

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00291213

YaleHIC26585

Details and patient eligibility

About

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Enrollment: 50 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: meet Glazer Morgenstern criteria for TD -

Exclusion Criteria: none

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups, including a placebo group

Levetiracetram Administration

Experimental group

Treatment:

Drug: levetiracetam

Placebo

Placebo Comparator group

Treatment:

Drug: placebo